$
3.760
+0.01(0.267%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.910
Open
3.910
VWAP
3.75
Vol
160.19K
Mkt Cap
38.32M
Low
3.700
Amount
600.03K
EV/EBITDA(TTM)
--
Total Shares
4.80M
EV
35.73M
EV/OCF(TTM)
--
P/S(TTM)
--
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.307
-71.34%
--
--
-0.370
-69.67%
--
--
-0.577
-53.87%
Estimates Revision
The market is revising No Change the revenue expectations for PolyPid Ltd. (PYPD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 36.73%.
EPS Estimates for FY2025
Revise Upward
up Image
+2.65%
In Past 3 Month
Stock Price
Go Up
up Image
+36.73%
In Past 3 Month
4 Analyst Rating
up Image
219.15% Upside
Wall Street analysts forecast PYPD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYPD is 12.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image
219.15% Upside
Current: 3.760
sliders
Low
9.00
Averages
12.00
High
14.00
Roth Capital
Buy
downgrade
$12 -> $9
2025-06-19
Reason
Roth Capital lowered the firm's price target on PolyPid to $9 from $12 and keeps a Buy rating on the shares. The firm is updating its model after the company has executed a new financing agreement that will infuse $27M worth of cash into its coffers, allowing PolyPid to schedule a pre-NDA, New Drug Application, meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026, the analyst tells investors in a research note.
Citizens JMP
Outperform
downgrade
$16 -> $14
2025-06-18
Reason
Citizens JMP lowered the firm's price target on PolyPid to $14 from $16 and keeps an Outperform rating on the shares after the company announced that it anticipates gross proceeds of $26.7M from the exercise of 7.6M existing warrants that have been re-priced to a $3.50 exercise price and that it will issue another 7.6M warrants at $4.50. The firm's confidence is bolstered in the potential for D-PLEX100 to get to market following the warrant exercise, the analyst tells investors in a research note.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$12 -> $9
2025-06-18
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on PolyPid to $9 from $12 primarily due to a higher forecasted share count in Q1 2026, while keeping a Buy rating on the shares. The firm notes PolyPid has executed a new financing agreement that will infuse about $27M worth of cash into its coffers, allowing the company to schedule a pre-NDA meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026.
H.C. Wainwright
Brandon Folkes
Buy
upgrade
$11 -> $13
2025-06-09
Reason
Roth Capital
Boobalan Pachaiyappan
Buy
initiated
$9
2025-06-05
Reason
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of PolyPid with a Buy rating and $9 price target. The firm says its optimism on the shares is driven by D-PLEX100's utility in curbing surgical site infection, particularly in patients undergoing colorectal cancer surgery. The company's current cash position and potential near-term dilution could be balanced by D-PLEX100's new drug application filing in the first half of 2026 and sales potential of over $800M in 2035, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
initiated
$11
2025-06-02
Reason

Valuation Metrics

The current forward P/E ratio for PolyPid Ltd (PYPD.O) is -2.59, compared to its 5-year average forward P/E of -2.26. For a more detailed relative valuation and DCF analysis to assess PolyPid Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.26
Current PE
-2.59
Overvalued PE
-0.46
Undervalued PE
-4.05

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.60
Undervalued EV/EBITDA
-3.08

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
47.05
Current PS
0.00
Overvalued PS
244.68
Undervalued PS
-150.57

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+20.28%
-7.58M
Operating Profit
FY2025Q1
YoY :
+28.23%
-8.27M
Net Income after Tax
FY2025Q1
YoY :
-48.91%
-0.70
EPS - Diluted
FY2020Q1
-5.16M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PYPD News & Events

Events Timeline

2025-07-15 (ET)
2025-07-15
08:13:31
PolyPid unveils long-acting GLP-1 receptor agonists delivery platform
select
2025-06-09 (ET)
2025-06-09
07:37:59
PolyPid announces topline results from Phase 3 SHIELD II trial
select
2025-05-14 (ET)
2025-05-14
07:07:39
PolyPid reports Q1 EPS 70c vs $1.37 last year
select
Sign Up For More Events

News

5.0
07-15Newsfilter
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
6.5
06-21TipRanks
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
4.0
06-18Benzinga
Roth Capital Maintains Buy on PolyPid, Lowers Price Target to $9
Sign Up For More News

FAQ

arrow icon

What is PolyPid Ltd (PYPD) stock price today?

The current price of PYPD is 3.76 USD — it has increased 0.27 % in the last trading day.

arrow icon

What is PolyPid Ltd (PYPD)'s business?

arrow icon

What is the price predicton of PYPD Stock?

arrow icon

What is PolyPid Ltd (PYPD)'s revenue for the last quarter?

arrow icon

What is PolyPid Ltd (PYPD)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for PolyPid Ltd (PYPD)'s fundamentals?

arrow icon

How many employees does PolyPid Ltd (PYPD). have?

arrow icon

What is PolyPid Ltd (PYPD) market cap?